STOCK TITAN

Vanguard disaggregates holdings; reports 0% in CVS (NYSE: CVS)

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

CVS Health Corp — The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A describing an internal realignment and reporting 0 shares and 0% beneficial ownership of CVS common stock. The filing notes the realignment took place January 12, 2026 and the amendment is signed on 03/26/2026.

Positive

  • None.

Negative

  • None.

Insights

Amendment documents structural reporting change, not a trade.

The filing explains an internal realignment at The Vanguard Group, Inc. on January 12, 2026 and states certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538.

Because the amendment reports 0 shares and 0% ownership, it represents an administrative reporting update rather than a change in CVS ownership disclosed here.

Disaggregated reporting can clarify which Vanguard entities hold positions.

The form states the disaggregation means subsidiaries or business divisions will report separately; the filing lists address and certifies no single other person holds >5% of the reported securities.

Investors seeking holder-level detail should track subsequent Schedule 13 filings by Vanguard subsidiaries for any disclosed positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did the Amendment No. 10 to Schedule 13G/A for CVS (CVS) report?

It reports that The Vanguard Group underwent an internal realignment and disaggregated reporting; the amendment states 0 shares and 0% beneficial ownership as signed on 03/26/2026.

Does The Vanguard Group currently own CVS shares according to this filing?

According to this amendment, The Vanguard Group reports holding 0 shares and 0% of CVS common stock in the Schedule 13G/A filing signed on 03/26/2026.

Why does the filing mention an internal realignment on January 12, 2026?

The filing explains the realignment caused certain Vanguard subsidiaries/divisions to report beneficial ownership separately, relying on SEC Release No. 34-39538, so holdings are disaggregated across entities.

Will other Vanguard entities report CVS holdings after this disaggregation?

Yes; the amendment states subsidiaries or business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538, so related Schedule 13 filings may show holdings.

Who signed the Schedule 13G/A amendment for CVS and when?

The amendment was signed by Ashley Grim, Head of Global Fund Administration, with the signature date shown as 03/26/2026 on the filing.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026